HUTCHMED (China) Limited (NASDAQ: HCM) Stock Competitors & Peer Comparison
See HCM's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for HCM and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCM | $12.51 | +5.75% | 2.2B | 4.69 | $2.67 | N/A |
| TAK | $17.45 | +2.53% | 55.5B | 12.55 | $1.39 | +3.61% |
| HLN | $10.03 | +0.00% | 44.2B | 25.11 | $0.40 | +1.76% |
| TEVA | $35.36 | +1.58% | 41.2B | 12.06 | $2.93 | N/A |
| VTRS | $16.43 | +0.86% | 19.1B | 6.52 | $2.52 | +2.90% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| ELAN | $22.12 | -8.60% | 11B | 20.86 | $1.06 | N/A |
| RDY | $12.22 | +0.91% | 10.2B | 20.01 | $0.61 | +0.68% |
| LNTH | $100.95 | -0.12% | 6.6B | 16.97 | $5.95 | N/A |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
HCM vs TAK Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TAK has a market cap of 55.5B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while TAK trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas TAK's P/E ratio is 12.55. In terms of profitability, HCM's ROE is +0.01%, compared to TAK's ROE of +0.02%. Regarding short-term risk, HCM is more volatile compared to TAK. This indicates higher risk in terms of short-term price fluctuations for HCM.Check TAK's competition here
Haleon plc (NYSE: HLN)
HCM vs HLN Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, HLN has a market cap of 44.2B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while HLN trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas HLN's P/E ratio is 25.11. In terms of profitability, HCM's ROE is +0.01%, compared to HLN's ROE of +0.17%. Regarding short-term risk, HCM is more volatile compared to HLN. This indicates higher risk in terms of short-term price fluctuations for HCM.Check HLN's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
HCM vs TEVA Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TEVA has a market cap of 41.2B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while TEVA trades at $35.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas TEVA's P/E ratio is 12.06. In terms of profitability, HCM's ROE is +0.01%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, HCM is more volatile compared to TEVA. This indicates higher risk in terms of short-term price fluctuations for HCM.Check TEVA's competition here
Viatris Inc. (NASDAQ: VTRS)
HCM vs VTRS Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, VTRS has a market cap of 19.1B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while VTRS trades at $16.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas VTRS's P/E ratio is 6.52. In terms of profitability, HCM's ROE is +0.01%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, HCM is more volatile compared to VTRS. This indicates higher risk in terms of short-term price fluctuations for HCM.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
HCM vs ITCI Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HCM's ROE is +0.01%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, HCM is more volatile compared to ITCI. This indicates higher risk in terms of short-term price fluctuations for HCM.Check ITCI's competition here
Catalent, Inc. (NYSE: CTLT)
HCM vs CTLT Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HCM's ROE is +0.01%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, HCM is more volatile compared to CTLT. This indicates higher risk in terms of short-term price fluctuations for HCM.Check CTLT's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
HCM vs ELAN Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ELAN has a market cap of 11B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ELAN trades at $22.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ELAN's P/E ratio is 20.86. In terms of profitability, HCM's ROE is +0.01%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for HCM.Check ELAN's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
HCM vs RDY Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, RDY has a market cap of 10.2B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while RDY trades at $12.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas RDY's P/E ratio is 20.01. In terms of profitability, HCM's ROE is +0.01%, compared to RDY's ROE of +0.09%. Regarding short-term risk, HCM is more volatile compared to RDY. This indicates higher risk in terms of short-term price fluctuations for HCM.Check RDY's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
HCM vs LNTH Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, LNTH has a market cap of 6.6B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while LNTH trades at $100.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas LNTH's P/E ratio is 16.97. In terms of profitability, HCM's ROE is +0.01%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, HCM is more volatile compared to LNTH. This indicates higher risk in terms of short-term price fluctuations for HCM.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
HCM vs AMRX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AMRX has a market cap of 5.8B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while AMRX trades at $18.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas AMRX's P/E ratio is 20.16. In terms of profitability, HCM's ROE is +0.01%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, HCM is more volatile compared to AMRX. This indicates higher risk in terms of short-term price fluctuations for HCM.Check AMRX's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
HCM vs INDV Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, INDV has a market cap of 4.8B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while INDV trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas INDV's P/E ratio is 10.64. In terms of profitability, HCM's ROE is +0.01%, compared to INDV's ROE of -2.16%. Regarding short-term risk, HCM is more volatile compared to INDV. This indicates higher risk in terms of short-term price fluctuations for HCM.Check INDV's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
HCM vs SUPN Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while SUPN trades at $47.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas SUPN's P/E ratio is 15.57. In terms of profitability, HCM's ROE is +0.01%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, HCM is more volatile compared to SUPN. This indicates higher risk in terms of short-term price fluctuations for HCM.Check SUPN's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
HCM vs RGC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, RGC has a market cap of 2.7B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while RGC trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas RGC's P/E ratio is -380.99. In terms of profitability, HCM's ROE is +0.01%, compared to RGC's ROE of -2.32%. Regarding short-term risk, HCM is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for HCM.Check RGC's competition here
Bausch Health Companies Inc. (NYSE: BHC)
HCM vs BHC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, BHC has a market cap of 2.3B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while BHC trades at $6.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas BHC's P/E ratio is 1.59. In terms of profitability, HCM's ROE is +0.01%, compared to BHC's ROE of +0.89%. Regarding short-term risk, HCM is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for HCM.Check BHC's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
HCM vs DCPH Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HCM's ROE is +0.01%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, HCM is more volatile compared to DCPH. This indicates higher risk in terms of short-term price fluctuations for HCM.Check DCPH's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
HCM vs AVDL Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, HCM's ROE is +0.01%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, HCM is more volatile compared to AVDL. This indicates higher risk in terms of short-term price fluctuations for HCM.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
HCM vs EMBCV Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.01%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, HCM is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for HCM.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
HCM vs DVAX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas DVAX's P/E ratio is -41.89. In terms of profitability, HCM's ROE is +0.01%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, HCM is more volatile compared to DVAX. This indicates higher risk in terms of short-term price fluctuations for HCM.Check DVAX's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
HCM vs ANIP Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ANIP trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ANIP's P/E ratio is 9.52. In terms of profitability, HCM's ROE is +0.01%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, HCM is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for HCM.Check ANIP's competition here
Perrigo Company plc (NYSE: PRGO)
HCM vs PRGO Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PRGO has a market cap of 1.8B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while PRGO trades at $12.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas PRGO's P/E ratio is 5.13. In terms of profitability, HCM's ROE is +0.01%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, HCM is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for HCM.Check PRGO's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
HCM vs TARO Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas TARO's P/E ratio is 30.05. In terms of profitability, HCM's ROE is +0.01%, compared to TARO's ROE of +0.03%. Regarding short-term risk, HCM is more volatile compared to TARO. This indicates higher risk in terms of short-term price fluctuations for HCM.Check TARO's competition here
Harrow Health, Inc. (NASDAQ: HROW)
HCM vs HROW Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, HROW has a market cap of 1.5B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while HROW trades at $40.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas HROW's P/E ratio is 449.33. In terms of profitability, HCM's ROE is +0.01%, compared to HROW's ROE of -0.34%. Regarding short-term risk, HCM is more volatile compared to HROW. This indicates higher risk in terms of short-term price fluctuations for HCM.Check HROW's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
HCM vs PAHC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while PAHC trades at $34.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas PAHC's P/E ratio is 11.70. In terms of profitability, HCM's ROE is +0.01%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, HCM is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for HCM.Check PAHC's competition here
Alvotech (NASDAQ: ALVO)
HCM vs ALVO Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ALVO has a market cap of 1.3B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ALVO trades at $3.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ALVO's P/E ratio is -11.21. In terms of profitability, HCM's ROE is +0.01%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, HCM is more volatile compared to ALVO. This indicates higher risk in terms of short-term price fluctuations for HCM.Check ALVO's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
HCM vs ETON Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ETON trades at $44.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ETON's P/E ratio is -637.14. In terms of profitability, HCM's ROE is +0.01%, compared to ETON's ROE of -0.06%. Regarding short-term risk, HCM is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for HCM.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
HCM vs CRON Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while CRON trades at $3.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas CRON's P/E ratio is 29.44. In terms of profitability, HCM's ROE is +0.01%, compared to CRON's ROE of +0.06%. Regarding short-term risk, HCM is more volatile compared to CRON. This indicates higher risk in terms of short-term price fluctuations for HCM.Check CRON's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
HCM vs PCRX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PCRX has a market cap of 984.2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while PCRX trades at $25.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas PCRX's P/E ratio is 9.62. In terms of profitability, HCM's ROE is +0.01%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, HCM is more volatile compared to PCRX. This indicates higher risk in terms of short-term price fluctuations for HCM.Check PCRX's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
HCM vs COLL Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, COLL has a market cap of 955.8M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while COLL trades at $29.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas COLL's P/E ratio is 3.70. In terms of profitability, HCM's ROE is +0.01%, compared to COLL's ROE of +0.16%. Regarding short-term risk, HCM is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for HCM.Check COLL's competition here
PetIQ, Inc. (NASDAQ: PETQ)
HCM vs PETQ Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HCM's ROE is +0.01%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, HCM is more volatile compared to PETQ. This indicates higher risk in terms of short-term price fluctuations for HCM.Check PETQ's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
HCM vs AMPH Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AMPH has a market cap of 916.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while AMPH trades at $20.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas AMPH's P/E ratio is 7.09. In terms of profitability, HCM's ROE is +0.01%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, HCM is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for HCM.Check AMPH's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
HCM vs IRWD Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, IRWD has a market cap of 711.1M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while IRWD trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas IRWD's P/E ratio is 5.54. In terms of profitability, HCM's ROE is +0.01%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, HCM is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for HCM.Check IRWD's competition here
Evotec SE (NASDAQ: EVO)
HCM vs EVO Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EVO has a market cap of 710.5M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while EVO trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas EVO's P/E ratio is -2.82. In terms of profitability, HCM's ROE is +0.01%, compared to EVO's ROE of -0.24%. Regarding short-term risk, HCM is more volatile compared to EVO. This indicates higher risk in terms of short-term price fluctuations for HCM.Check EVO's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
HCM vs BDSI Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HCM's ROE is +0.01%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HCM is more volatile compared to BDSI. This indicates higher risk in terms of short-term price fluctuations for HCM.Check BDSI's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
HCM vs TLRY Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TLRY has a market cap of 511.1M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while TLRY trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas TLRY's P/E ratio is -7.21. In terms of profitability, HCM's ROE is +0.01%, compared to TLRY's ROE of -0.08%. Regarding short-term risk, HCM is more volatile compared to TLRY. This indicates higher risk in terms of short-term price fluctuations for HCM.Check TLRY's competition here
Evolus, Inc. (NASDAQ: EOLS)
HCM vs EOLS Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EOLS has a market cap of 499.8M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while EOLS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas EOLS's P/E ratio is -24.04. In terms of profitability, HCM's ROE is +0.01%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, HCM is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for HCM.Check EOLS's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
HCM vs AQST Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AQST has a market cap of 494.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while AQST trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas AQST's P/E ratio is -6.46. In terms of profitability, HCM's ROE is +0.01%, compared to AQST's ROE of +1.91%. Regarding short-term risk, HCM is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for HCM.Check AQST's competition here
Kamada Ltd. (NASDAQ: KMDA)
HCM vs KMDA Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, KMDA has a market cap of 419.4M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while KMDA trades at $7.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas KMDA's P/E ratio is 20.77. In terms of profitability, HCM's ROE is +0.01%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, HCM is more volatile compared to KMDA. This indicates higher risk in terms of short-term price fluctuations for HCM.Check KMDA's competition here
Canopy Growth Corporation (NASDAQ: CGC)
HCM vs CGC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CGC has a market cap of 409.5M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while CGC trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas CGC's P/E ratio is -0.58. In terms of profitability, HCM's ROE is +0.01%, compared to CGC's ROE of -0.31%. Regarding short-term risk, HCM is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for HCM.Check CGC's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
HCM vs TKNO Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TKNO has a market cap of 346.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while TKNO trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas TKNO's P/E ratio is -20.84. In terms of profitability, HCM's ROE is +0.01%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, HCM is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for HCM.Check TKNO's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
HCM vs ALIM Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HCM's ROE is +0.01%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, HCM is more volatile compared to ALIM. This indicates higher risk in terms of short-term price fluctuations for HCM.Check ALIM's competition here
Landec Corporation (NASDAQ: LNDC)
HCM vs LNDC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HCM's ROE is +0.01%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, HCM is more volatile compared to LNDC. This indicates higher risk in terms of short-term price fluctuations for HCM.Check LNDC's competition here
Embecta Corp. (NASDAQ: EMBC)
HCM vs EMBC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EMBC has a market cap of 262.2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while EMBC trades at $4.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas EMBC's P/E ratio is 1.70. In terms of profitability, HCM's ROE is +0.01%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, HCM is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for HCM.Check EMBC's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
HCM vs ORGO Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ORGO has a market cap of 239.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ORGO trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ORGO's P/E ratio is 62.00. In terms of profitability, HCM's ROE is +0.01%, compared to ORGO's ROE of -0.27%. Regarding short-term risk, HCM is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for HCM.Check ORGO's competition here
Shineco, Inc. (NASDAQ: TYHT)
HCM vs TYHT Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HCM's ROE is +0.01%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, HCM is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for HCM.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
HCM vs SIGA Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SIGA has a market cap of 218.8M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while SIGA trades at $3.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas SIGA's P/E ratio is 11.30. In terms of profitability, HCM's ROE is +0.01%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, HCM is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for HCM.Check SIGA's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
HCM vs LFCR Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, LFCR has a market cap of 187.9M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while LFCR trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas LFCR's P/E ratio is -4.68. In terms of profitability, HCM's ROE is +0.01%, compared to LFCR's ROE of -1.95%. Regarding short-term risk, HCM is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for HCM.Check LFCR's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
HCM vs ACB Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ACB has a market cap of 185.2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ACB trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ACB's P/E ratio is -6.10. In terms of profitability, HCM's ROE is +0.01%, compared to ACB's ROE of -0.21%. Regarding short-term risk, HCM is more volatile compared to ACB. This indicates higher risk in terms of short-term price fluctuations for HCM.Check ACB's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
HCM vs REPH Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas REPH's P/E ratio is -8.04. In terms of profitability, HCM's ROE is +0.01%, compared to REPH's ROE of -0.22%. Regarding short-term risk, HCM is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for HCM.Check REPH's competition here
Journey Medical Corporation (NASDAQ: DERM)
HCM vs DERM Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, DERM has a market cap of 177M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while DERM trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas DERM's P/E ratio is -17.38. In terms of profitability, HCM's ROE is +0.01%, compared to DERM's ROE of -0.36%. Regarding short-term risk, HCM is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for HCM.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
HCM vs CRDL Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CRDL has a market cap of 163.7M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while CRDL trades at $1.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas CRDL's P/E ratio is -5.05. In terms of profitability, HCM's ROE is +0.01%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, HCM is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for HCM.Check CRDL's competition here
Theratechnologies Inc. (NASDAQ: THTX)
HCM vs THTX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas THTX's P/E ratio is -28.83. In terms of profitability, HCM's ROE is +0.01%, compared to THTX's ROE of +0.17%. Regarding short-term risk, HCM is more volatile compared to THTX. This indicates higher risk in terms of short-term price fluctuations for HCM.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
HCM vs ASRT Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ASRT's P/E ratio is -7.10. In terms of profitability, HCM's ROE is +0.01%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, HCM is more volatile compared to ASRT. This indicates higher risk in terms of short-term price fluctuations for HCM.Check ASRT's competition here
Organigram Global Inc. (NASDAQ: OGI)
HCM vs OGI Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, OGI has a market cap of 139.4M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while OGI trades at $0.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas OGI's P/E ratio is -3.81. In terms of profitability, HCM's ROE is +0.01%, compared to OGI's ROE of -0.07%. Regarding short-term risk, HCM is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for HCM.Check OGI's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
HCM vs CPIX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CPIX has a market cap of 116.9M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while CPIX trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas CPIX's P/E ratio is -19.50. In terms of profitability, HCM's ROE is +0.01%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, HCM is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for HCM.Check CPIX's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
HCM vs SCTL Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HCM's ROE is +0.01%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, HCM is more volatile compared to SCTL. This indicates higher risk in terms of short-term price fluctuations for HCM.Check SCTL's competition here
Procaps Group S.A. (NASDAQ: PROC)
HCM vs PROC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas PROC's P/E ratio is 1.53. In terms of profitability, HCM's ROE is +0.01%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HCM is more volatile compared to PROC. This indicates higher risk in terms of short-term price fluctuations for HCM.Check PROC's competition here
OptiNose, Inc. (NASDAQ: OPTN)
HCM vs OPTN Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas OPTN's P/E ratio is -4.42. In terms of profitability, HCM's ROE is +0.01%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, HCM is more volatile compared to OPTN. This indicates higher risk in terms of short-term price fluctuations for HCM.Check OPTN's competition here
Zomedica Corp. (AMEX: ZOM)
HCM vs ZOM Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HCM's ROE is +0.01%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, HCM is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for HCM.Check ZOM's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
HCM vs ZYBT Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ZYBT has a market cap of 89.6M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ZYBT trades at $1.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ZYBT's P/E ratio is -8.59. In terms of profitability, HCM's ROE is +0.01%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, HCM is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for HCM.Check ZYBT's competition here
Upexi, Inc. (NASDAQ: GRVI)
HCM vs GRVI Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HCM's ROE is +0.01%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, HCM is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for HCM.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
HCM vs ZYNE Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HCM's ROE is +0.01%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HCM is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for HCM.Check ZYNE's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
HCM vs SSIC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HCM's ROE is +0.01%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, HCM is more volatile compared to SSIC. This indicates higher risk in terms of short-term price fluctuations for HCM.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
HCM vs VLNS Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HCM's ROE is +0.01%, compared to VLNS's ROE of N/A. Regarding short-term risk, HCM is more volatile compared to VLNS. This indicates higher risk in terms of short-term price fluctuations for HCM.Check VLNS's competition here
BGM Group Ltd. (NASDAQ: BGM)
HCM vs BGM Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, BGM has a market cap of 60.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while BGM trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas BGM's P/E ratio is -1.04. In terms of profitability, HCM's ROE is +0.01%, compared to BGM's ROE of -0.07%. Regarding short-term risk, HCM is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for HCM.Check BGM's competition here
DURECT Corporation (NASDAQ: DRRX)
HCM vs DRRX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas DRRX's P/E ratio is -4.44. In terms of profitability, HCM's ROE is +0.01%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, HCM is more volatile compared to DRRX. This indicates higher risk in terms of short-term price fluctuations for HCM.Check DRRX's competition here
InterCure Ltd. (NASDAQ: INCR)
HCM vs INCR Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, INCR has a market cap of 58M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while INCR trades at $0.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas INCR's P/E ratio is -2.26. In terms of profitability, HCM's ROE is +0.01%, compared to INCR's ROE of -0.09%. Regarding short-term risk, HCM is more volatile compared to INCR. This indicates higher risk in terms of short-term price fluctuations for HCM.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
HCM vs JUPW Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HCM's ROE is +0.01%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, HCM is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for HCM.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
HCM vs QLI Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas QLI's P/E ratio is -4.92. In terms of profitability, HCM's ROE is +0.01%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HCM is more volatile compared to QLI. This indicates higher risk in terms of short-term price fluctuations for HCM.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
HCM vs HEXO Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HCM's ROE is +0.01%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HCM is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for HCM.Check HEXO's competition here
Talphera, Inc. (NASDAQ: TLPH)
HCM vs TLPH Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TLPH has a market cap of 29.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while TLPH trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas TLPH's P/E ratio is -4.61. In terms of profitability, HCM's ROE is +0.01%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, HCM is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for HCM.Check TLPH's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
HCM vs RMTI Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, RMTI has a market cap of 28.5M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while RMTI trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas RMTI's P/E ratio is -6.89. In terms of profitability, HCM's ROE is +0.01%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, HCM is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for HCM.Check RMTI's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
HCM vs AYTU Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AYTU has a market cap of 25.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while AYTU trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas AYTU's P/E ratio is -1.23. In terms of profitability, HCM's ROE is +0.01%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, HCM is more volatile compared to AYTU. This indicates higher risk in terms of short-term price fluctuations for HCM.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
HCM vs TXMD Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, TXMD has a market cap of 24M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while TXMD trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas TXMD's P/E ratio is 105.45. In terms of profitability, HCM's ROE is +0.01%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, HCM is more volatile compared to TXMD. This indicates higher risk in terms of short-term price fluctuations for HCM.Check TXMD's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
HCM vs CYTH Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HCM's ROE is +0.01%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, HCM is more volatile compared to CYTH. This indicates higher risk in terms of short-term price fluctuations for HCM.Check CYTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
HCM vs EVOK Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas EVOK's P/E ratio is -7.97. In terms of profitability, HCM's ROE is +0.01%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, HCM is more volatile compared to EVOK. This indicates higher risk in terms of short-term price fluctuations for HCM.Check EVOK's competition here
Biofrontera Inc. (NASDAQ: BFRIW)
HCM vs BFRIW Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, BFRIW has a market cap of 17M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while BFRIW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, HCM's ROE is +0.01%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, HCM is less volatile compared to BFRIW. This indicates lower risk in terms of short-term price fluctuations for HCM.Check BFRIW's competition here
Optimi Health Corp. (NASDAQ: OPTH)
HCM vs OPTH Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, OPTH has a market cap of 16.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while OPTH trades at $5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas OPTH's P/E ratio is -18.56. In terms of profitability, HCM's ROE is +0.01%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, HCM is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for HCM.Check OPTH's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
HCM vs ACRX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HCM's ROE is +0.01%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, HCM is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for HCM.Check ACRX's competition here
Cosmos Health Inc. (NASDAQ: COSM)
HCM vs COSM Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, COSM has a market cap of 12.7M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while COSM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas COSM's P/E ratio is -0.38. In terms of profitability, HCM's ROE is +0.01%, compared to COSM's ROE of -0.96%. Regarding short-term risk, HCM is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for HCM.Check COSM's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
HCM vs AGRX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HCM's ROE is +0.01%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, HCM is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for HCM.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
HCM vs NLTX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HCM's ROE is +0.01%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, HCM is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for HCM.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
HCM vs LCI Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas LCI's P/E ratio is -0.04. In terms of profitability, HCM's ROE is +0.01%, compared to LCI's ROE of +1.66%. Regarding short-term risk, HCM is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for HCM.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
HCM vs ADMP Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ADMP's P/E ratio is -0.08. In terms of profitability, HCM's ROE is +0.01%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, HCM is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for HCM.Check ADMP's competition here
cbdMD, Inc. (AMEX: YCBD)
HCM vs YCBD Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas YCBD's P/E ratio is -1.38. In terms of profitability, HCM's ROE is +0.01%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, HCM is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for HCM.Check YCBD's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
HCM vs GELS Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, GELS has a market cap of 5M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while GELS trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas GELS's P/E ratio is -1.09. In terms of profitability, HCM's ROE is +0.01%, compared to GELS's ROE of -0.25%. Regarding short-term risk, HCM is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for HCM.Check GELS's competition here
Mallinckrodt plc (AMEX: MNK)
HCM vs MNK Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas MNK's P/E ratio is -0.44. In terms of profitability, HCM's ROE is +0.01%, compared to MNK's ROE of -0.26%. Regarding short-term risk, HCM is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for HCM.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
HCM vs FLGC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas FLGC's P/E ratio is -0.19. In terms of profitability, HCM's ROE is +0.01%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, HCM is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for HCM.Check FLGC's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
HCM vs CPHI Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CPHI has a market cap of 3.6M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while CPHI trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas CPHI's P/E ratio is -1.76. In terms of profitability, HCM's ROE is +0.01%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, HCM is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for HCM.Check CPHI's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
HCM vs UPC Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, UPC has a market cap of 3.5M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while UPC trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas UPC's P/E ratio is -0.69. In terms of profitability, HCM's ROE is +0.01%, compared to UPC's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for HCM.Check UPC's competition here
Sunshine Biopharma, Inc. (NASDAQ: SBFM)
HCM vs SBFM Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SBFM has a market cap of 2.9M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while SBFM trades at $1.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas SBFM's P/E ratio is -0.20. In terms of profitability, HCM's ROE is +0.01%, compared to SBFM's ROE of -0.26%. Regarding short-term risk, HCM is less volatile compared to SBFM. This indicates lower risk in terms of short-term price fluctuations for HCM.Check SBFM's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
HCM vs SHPH Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SHPH has a market cap of 2.6M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while SHPH trades at $4.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas SHPH's P/E ratio is -0.20. In terms of profitability, HCM's ROE is +0.01%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, HCM is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for HCM.Check SHPH's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
HCM vs PLXP Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas PLXP's P/E ratio is -0.22. In terms of profitability, HCM's ROE is +0.01%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, HCM is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for HCM.Check PLXP's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
HCM vs SNOA Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, SNOA has a market cap of 2.4M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while SNOA trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas SNOA's P/E ratio is -1.22. In terms of profitability, HCM's ROE is +0.01%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, HCM is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for HCM.Check SNOA's competition here
Athenex, Inc. (NASDAQ: ATNX)
HCM vs ATNX Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas ATNX's P/E ratio is -0.02. In terms of profitability, HCM's ROE is +0.01%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, HCM is more volatile compared to ATNX. This indicates higher risk in terms of short-term price fluctuations for HCM.Check ATNX's competition here
Procaps Group, S.A. (NASDAQ: PROCW)
HCM vs PROCW Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas PROCW's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.01%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, HCM is more volatile compared to PROCW. This indicates higher risk in terms of short-term price fluctuations for HCM.Check PROCW's competition here
RedHill Biopharma Ltd. (NASDAQ: RDHL)
HCM vs RDHL Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, RDHL has a market cap of 1.9M. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while RDHL trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas RDHL's P/E ratio is 0.12. In terms of profitability, HCM's ROE is +0.01%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, HCM is less volatile compared to RDHL. This indicates lower risk in terms of short-term price fluctuations for HCM.Check RDHL's competition here
cbdMD, Inc. (AMEX: YCBD-PA)
HCM vs YCBD-PA Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, YCBD-PA has a market cap of 928.2K. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while YCBD-PA trades at $1.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas YCBD-PA's P/E ratio is -2.69. In terms of profitability, HCM's ROE is +0.01%, compared to YCBD-PA's ROE of -0.34%. Regarding short-term risk, HCM is less volatile compared to YCBD-PA. This indicates lower risk in terms of short-term price fluctuations for HCM.Check YCBD-PA's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTHW)
HCM vs CYTHW Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, CYTHW has a market cap of 928K. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while CYTHW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas CYTHW's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.01%, compared to CYTHW's ROE of -7.30%. Regarding short-term risk, HCM is more volatile compared to CYTHW. This indicates higher risk in terms of short-term price fluctuations for HCM.Check CYTHW's competition here
Lucy Scientific Discovery Inc. (NASDAQ: LSDI)
HCM vs LSDI Comparison August 2026
HUTCHMED (China) Limited (NASDAQ: HCM) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 2.2B. In comparison, LSDI has a market cap of 906.9K. Regarding current trading prices, HCM is priced at $12.51 on the NASDAQ, while LSDI trades at $0.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.69, whereas LSDI's P/E ratio is -0.07. In terms of profitability, HCM's ROE is +0.01%, compared to LSDI's ROE of +181.47%. Regarding short-term risk, HCM is less volatile compared to LSDI. This indicates lower risk in terms of short-term price fluctuations for HCM.Check LSDI's competition here